News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pivotal Therapeutics Inc. Announces First Prescription Sales in the United States


5/22/2012 10:09:49 AM

WOODBRIDGE, Ontario--(BUSINESS WIRE)--Pivotal Therapeutics Inc. (CNSX: PVO; OTCQX: PVTTF), a specialty pharmaceutical company with a focus on cardiovascular health, is pleased to announce that prescription sales have begun in the United States for its lead therapeutic VASCAZEN™. A prescription-only medical food for the aid in the dietary management of Omega-3 deficient cardiovascular disease patients, VASCAZEN™ is now available through prescription in a vast majority of pharmacies throughout the US and is receiving partial reimbursement from a growing number of the nations largest private insurers.

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES